Getinge B, SE0000202624

Getinge B stock gains as ABG Sundal Collier raises rating and target

Published on 09/07/2026 at 19:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Getinge B stock is trading higher on September 7, 2026 after ABG Sundal Collier upgraded the shares to buy and lifted its target price, while recent quarterly figures keep the medical technology group in focus for investors.

OP-Saal mit Operationstisch, Leuchten und Monitoren in Klinik — Getinge AB (ISIN SE0000202624) zeigt hier einen modernen OP-Saal mit chirurgischem Tisch und Beleuchtung, Illustration mit AI erstellt.

Getinge B stock (ISIN SE0000202624) is trading around SEK 244 on Nasdaq Stockholm on September 7, 2026, modestly above its latest closing price of SEK 241.80 as investors react to a fresh analyst upgrade and a higher target price.

Analyst upgrade lifts Getinge B stock

According to MarketScreener, ABG Sundal Collier on September 7, 2026 raised its rating on Getinge from hold to buy and increased its target price from SEK 225 to SEK 285, implying a potential upside of roughly 17 percent from the latest levels and marking a clear vote of confidence in the stock’s earnings trajectory.

The same analyst overview shows that UBS initiated coverage of Getinge on September 2, 2026 with a neutral rating and a target price of SEK 255, positioning its view between the new, more optimistic ABG Sundal Collier target and the broader analyst consensus target of SEK 247.60 as of early September 2026.

Recent price performance and trading context

Live estimates from MarketScreener on September 7, 2026 indicate Getinge B trading around SEK 245.30, up 1.45% on the day, compared with a latest closing price of SEK 241.80, underscoring that the market is responding positively to the analyst upgrade.

Another snapshot cited by MarketScreener shows a last closing price of SEK 241.80 and a five-day change of about +1.08%, while the year-to-date performance stands near +11.75%, indicating that Getinge B stock has already delivered a double-digit return in 2026 before the latest rating change.

Business profile and product focus

Getinge AB is a Sweden-based medical technology company that provides equipment and solutions for healthcare and life science customers, including products used in operating rooms, intensive care units and sterile processing departments.

Stock price and market data

On Nasdaq Stockholm as of September 7, 2026, Getinge B stock is quoted around SEK 244.00, roughly 0.9% above its latest closing price of SEK 241.80, with the move largely linked to the shift in analyst sentiment and the higher SEK 285 target from ABG Sundal Collier.